The video and the infographic below explain the Calreticulin (CALR) DEL 52 mutation in relation to Essential Thrombocythemia (ET). The CALR variant DEL 52, results in the deletion of KDEL from the CALR protein, which is associated with activation of the STAT5 signaling pathway, known to induce cell proliferation and oncogenesis.
Share this page to spread the awareness of MPN and Essential Thrombocythemia.
To find out more about molecular profiling, prognostic modelling and collaborative care in myeloproliferative neoplasm patient management view Professor Kiladjian’s webinar.
Watch Professor Harrison’s talk on the additional considerations that should be made when treating female Essential Thrombocythemia patients.